Abstract:A tetranuclear Cu(II) complex of a pentadentate ligand, containing pyridine2,6‐diamide motif, is reported. The X‐ray structure of the complex reveals that it has an open book type architecture. The magnetic property of the complex is explored by VT susceptibility measurements and DFT calculations. The complex shows strong antiproliferative activity against HCT116 cancer cells. Possible mechanism of anticancer activity is also discussed. A pentadentate diamide ligand, N,N′‐di(pyridine‐2‐yl)pyridine‐2,6‐dicarboxamide (L1H2) and its tetranuclear Cu(II) complex [Cu4(L1)2(μ3‐OH)2(H2O)3(ClO4)](ClO4) ⋅ H2O are reported. X‐ray crystal structure of the complex reveals that it has an open‐book type architecture. Two central copper atoms are connected to each other by two hydroxo bridges. Each of these two hydroxo bridges also connects the two central copper atoms to one of the two terminal copper atoms. Variable temperature susceptibility measurements show that χMT decreases with the temperature, indicating a strong antiferromagnetic behavior. With the help of DFT calculations the magnetic data was analyzed using the spin Hamiltonian H=−2 J1S3 ⋅ S4 −2 J2(S3 ⋅ S1+ S3 ⋅ S2+ S4 ⋅ S1+ S4 ⋅ S2)−2 J3S1 ⋅ S2 (where subscripts 1 and 2 refer to the terminal copper atoms and 3 and 4 refer to the central copper atoms). The best fit was obtained with 2 J1=−322 cm−1, 2 J2=+34.8 cm−1, 2 J3=−8.8 cm−1 and g=2.18, indicating a δ‐type interaction between terminal copper atoms. The complex proves to be an avid binder of ct‐DNA, with apparent binding constant (Kapp) value estimated as 1.536×107 M−1. In vitro experiments indicate that the Cu(II) complex reduced the proliferation of HCT116 cells among other cell lines. This reduction of cell proliferation may be attributed to the enhancement of intracellular ROS, along with modulation and disruption of cell cycle associated proteins. SKC conceptualized the project, arranged funding and involved in overall coordination among collaborators, analyzing the data, and writing the paper. AM was involved in doing the experimental work on synthesis of the compounds, carrying out analytical and spectroscopic measurements, collecting X‐ray crystallographic data and DNA binding experiments. MS, SM and KDS were involved in study of anticancer activities of the complex. SS helped in refining X‐ray structure of the complex. MC did the magnetic measurements and analysis whereas AF did the DFT calculations.

A polymeric copper complex based on a pyrazole derivative: Synthesis, spectroscopic, X‐ray, and biological activity studies

Square pyramidal Cu(II) Acylpyrazolone Complex: Synthesis, Characterization, Crystal structure, DFT and Hirshfeld analysis, in-vitro anti-cancer evaluation

Copper (II) complexes based bis(pyrazolyl)borate derivatives as efficient anticancer agents: synthesis, characterization, X-ray structure, cytotoxicity, molecular docking and QSAR studies

Novel binuclear copper(II) complexes with sulfanylpyrazole ligands: Synthesis, crystal structure, fungicidal, cytostatic and cytotoxic activity

Syntheses, Structures and Properties of Zn(II) and Cu(II) Complexes Based on N2-2-methylenepyridinyl 1,2,3-Triazole Ligand

Copper(Ii) Coordination Compounds Based On Bis-Hydrazones Of 2,6-Diacetylpyridine: Synthesis, Structure, And Cytotoxic Activity

Copper(II) complexes incorporated with 2,2-bipyridyl and 2,2′-(((1E,1′E)-1,4-phenylene-bis(methanylylidene))bis(azanylylidene)) diphenol derivatives: In-vitro interaction with DNA/BSA, DFT, molecular docking and cytotoxicity

Synthesis, Structure, and Properties of a Copper(II) Binuclear Complex Based on Trifluoromethyl Containing Bis(pyrazolyl)hydrazone

A Tetranuclear copper(II) Complex with a Pyridine‐2,6‐dicarboxamide Ligand: Structural and Magnetic Properties and In vitro Antiproliferative Activity Against Human Cancer Cells

Synthesis, Characterization, Crystal Structure and Antitumor Activities of a Novel Demethylcantharidato Bridged Copper(ii) Phenanthroline Complex

Copper(II) complexes containing hydrazone and bipyridine/phenanthroline ligands for anticancer application against breast cancer cells

Biological and cytoselective anticancer properties of copper(II)-polypyridyl complexes modulated by auxiliary methylated glycine ligand

De novo design and preparation, structural details, and cytotoxic response of a new water soluble (2,2′–bipy)–(phenylalaninato)– μ –chlorido–copper(II) drug candidate against resistant cancer cells

Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes

Biological activity and biomolecule interaction of pyridyl thiazole derivative and its copper complex

1‐Benzyl‐1H‐indazol‐3‐ol Copper(II) Derivatives as Anticancer Agents: In‐vitro Interaction with DNA/BSA, DFT, Molecular Docking and Cytotoxicity on MCF7 Cells

Polymer complexes: LXXIX—synthesis, characterization, geometrical structures, biological activity and molecular docking studies of azo dye complexes

Insights into Structure and Biological Activity of Copper(II) and Zinc(II) Complexes with Triazolopyrimidine Ligands

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Solvolthermal Synthesis and Crystal Structure of a Polymeric Copper Complex with 5-Methyltetrazolate Ligands

Antitumor activity of copper(II) complexes with Schiff bases derived from N'-tosylbenzene-1,2-diamine